ArticleBritish journal of cancer2022
Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma.
Article in British journal of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 45 citations in OpenAlex.
- SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Trial
- Article
- Carcinosarcoma of the Ovary Arising in the Background of a Mucinous Neoplasm Distinct From a Mural Nodule.Cureus · 2026Article
- MRI Findings of Ovarian Carcinosarcoma: A Retrospective Comparison With Endometrioid Carcinoma.Cureus · 2026Article
- High-throughput drug screening identifies EGFR/MAPK pathway targeting sensitivities in organoid models of ovarian carcinosarcoma.Journal of experimental & clinical cancer research : CR · 2026Article
- The development of ovarian carcinosarcoma from serous tubal intraepithelial carcinoma: an immunohistochemical case report with literature review.Frontiers in oncology · 2026Article
- Clinical Characteristics and Treatment Outcomes in Ovarian Carcinosarcoma: A Retrospective Cohort Study of 90 Cases.International journal of women's health · 2026Article
- Dissecting the histological heterogeneity of ovarian carcinosarcoma and high-grade serous ovarian cancer in primary and metastatic tumors by single-cell transcriptomic analysis.Chinese medical journal · 2025Article
- Real-world experience and prognostic factors in ovarian carcinosarcoma: a single-center retrospective study from China.Frontiers in oncology · 2025Article
- Early detection of left fallopian tube carcinosarcoma by transvaginal sonography: a case report and review of diagnostic challenges.Frontiers in oncology · 2025Article
- The impact of demographic, clinical, and treatment factors on overall survival in ovarian carcinosarcomas: a National Cancer Database study.Frontiers in oncology · 2025Article
- Stage IVB ovarian carcinosarcoma in BRCA wild-type patients: two case reports of unexpected long-term remission.Frontiers in oncology · 2025Article
- Ovarian carcinosarcoma of heterologous type occurring in an endometriotic cyst with 3-year recurrence-free survival: a case report and literature review.International cancer conference journal · 2025Article
- An Updated Review Summarizing the Pharmaceutical Efficacy of Genistein and its Nanoformulations in Ovarian Carcinoma.Current pharmaceutical design · 2025Review
- Molecular characteristics of tubo-ovarian carcinosarcoma at different anatomic locations.Virchows Archiv : an international journal of pathology · 2024Article
- Single-cell transcriptomics reveals tumor landscape in ovarian carcinosarcoma.Journal of Zhejiang University. Science. B · 2024Article
- Sigmoido-ovarian fistula complicating ovarian carcinosarcoma: a case report.Annals of medicine and surgery (2012) · 2024Article
- The survival benefit associated with complete macroscopic resection in epithelial ovarian cancer is histotype specific.JNCI cancer spectrum · 2024Article
- Initial Presentation of Ovarian Carcinosarcoma With Non-islet Cell Tumor Hypoglycemia: A Case Report.Cureus · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOvarian carcinosarcoma (OCS) is an uncommon, biphasic and highly aggressive ovarian cancer type, which has received relatively little research attention.
methodsWe curated the largest pathologically confirmed OCS cohort to date, performing detailed histopathological characterisation, analysis of features associated with survival and comparison against high-grade serous ovarian carcinoma (HGSOC).
resultsEighty-two OCS patients were identified; overall survival was poor (median 12.7 months). In all, 79% demonstrated epithelial components of high-grade serous (HGS) type, while 21% were endometrioid. Heterologous elements were common (chondrosarcoma in 32%, rhabdomyosarcoma in 21%, liposarcoma in 2%); chondrosarcoma was more frequent in OCS with endometrioid carcinomatous components. Earlier stage, complete resection and platinum-containing adjuvant chemotherapy were associated with prolonged survival; however, risk of relapse and mortality was high across all patient groups. Histological subclassification did not identify subgroups with distinct survival. Compared to HGSOC, OCS patients were older (P < 0.0001), more likely to be FIGO stage I (P = 0.025), demonstrated lower chemotherapy response rate (P = 0.001) and had significantly poorer survival (P < 0.0001).
conclusionOCS represents a distinct, highly lethal form of ovarian cancer for which new treatment strategies are urgently needed. Histological subclassification does not identify patient subgroups with distinct survival. Aggressive adjuvant chemotherapy should be considered for all cases, including those with early-stage disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.